DelveInsight’s “Benign Prostatic Hyperplasia – Pipeline Insights, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Benign prostatic hyperplasia: Overview
Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age.
The symptoms of Benign prostatic hyperplasia include:
Several key diagnostic tools and investigations are used to diagnose BPH in men who present with LUTS. The first and most important tool in the assessment and diagnosis of BPH is the medical history of the patient. By taking a detailed history, one can establish potential causes and relevant comorbidities of LUTS, some of which might contribute to LUTS. A physical examination, including a digital rectal examination (DRE) and urinalysis, is the next step in diagnosis. Further investigations, such as uroflowmetry and measuring PVR volume, should help to confirm the presence of obstructive symptoms attributable to BPH.
Pharmacologic treatment- Men with moderate to severe LUTS from BPH (AUASI score of 8 or higher) or mild LUTS that are deemed bothersome by the patient may be offered pharmacologic treatment. The 2 major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors. The PDE-5 inhibitor tadalafil is also approved by the Food and Drug Administration (FDA) for the treatment of BPH.
Non Pharmacologic treatment- In men with mild LUTS symptoms from BPH (usually defined as an AUASI score of 0–7), medical or surgical treatment is not required. In the Medical Therapy of Prostatic Symptoms Study,23 fewer than 5% of men with mild symptoms who did not receive treatment had a progression of their symptoms as defined by a 4-point or greater increase in their AUASI score. No cases of acute kidney injury due to obstructive uropathy occurred.
This segment of the Benign prostatic hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Topsalysin is a modified pore forming protein (proaerolysin) in phase III clinical trials for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. It was developed by Sophiris Bio, then licensed to Kissei for development.
OPK88004 is a Phase 2 drug that is a selective androgen receptor modulator. OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in decreased prostate specific antigen (PSA) levels, and as an agonist resulting in increased anabolic effects, such as increased lean body mass and physical function and decreased fat mass. The originator of this was Eli Lilly and now licensed by OPKO Health.
Further product details are provided in the report……..
This segment of the report provides insights about the different Benign prostatic hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 30+ key companies which are developing the therapies for Benign prostatic hyperplasia. The companies which have their Benign prostatic hyperplasia drug candidates in the most advanced stage, i.e. phase III include, Sophiris Bio.
DelveInsight’s report covers around 30+ products under different phases of clinical development like
Benign prostatic hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Benign prostrate hyperplasia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Benign prostatic hyperplasia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign prostatic hyperplasia drugs.
Benign prostatic hyperplasia Report Insights
Benign prostatic hyperplasia Report Assessment
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Benign prostatic hyperplasia: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Benign prostatic hyperplasia – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
• Benign prostatic hyperplasia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Benign prostatic hyperplasia Collaboration Deals
• Company-Company Collaborations (Licensing / Partnering) Analysis
• Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
• Comparative Analysis
Topsalysin: Sophiris Bio
• Product Description
• Research and Development
• Product Development Activities
Mid Stage Products (Phase II)
• Comparative Analysis
OPK88004: Eli lilly and Company
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Fadanafil: XuanZhu Pharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
• Comparative Analysis
Lenvatinib: Aiviva BioPharma
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Benign prostatic hyperplasia Key Companies
Benign prostatic hyperplasia Key Products
Benign prostatic hyperplasia - Unmet Needs
Benign prostatic hyperplasia - Market Drivers and Barriers
Benign prostatic hyperplasia - Future Perspectives and Conclusion
Benign prostatic hyperplasia Analyst Views
Benign prostatic hyperplasia Key Companies
Appendix
List of Tables
Table 1 Total Products for Benign prostatic hyperplasia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Benign prostatic hyperplasia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
• ASKA Pharmaceutical
• Otsuka Pharmaceutical
• Eli Lilly and Company
• XuanZhu Pharma
• Aiviva BioPharma
• Veru Helathcare
• Boryung Pharmaceutical
